News & insights

VoxCell BioInnovation and adMare BioInnovations Partner to Advance Novel Antibody Therapies in a Human-Relevant Vascularized Tissue Platform

Epitopea Announces Approval of OVACT Clinical Trial Application for CryptiVax-1001 in Advanced High-Grade Serous Ovarian Cancer

Thryv Therapeutics Commences Patient Dosing in Wave II Clinical Study for Long QT Syndrome and Receives FDA Fast Track Designation for THRV-1268

Kainova Therapeutics Expands Phase I / II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe

Grant to Develop a Machine Learning Platform to Accelerate the Development of the Company’s Dualase®-based Therapeutics

Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors

Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies

Ocythera Secures Seed Financing from adMare BioInnovations and Fonds Impulsion to Advance Therapies for Rare Bone Diseases

Thryv Therapeutics Launches Pivotal Wave II Phase 2/3 Study in Long QT Syndrome Type 2

Domain Therapeutics Rebrands as Kainova Therapeutics Advancing Its Clinical Pipeline of GPCR-Modulating Therapies

Find Therapeutics Announces Series A Extension Financing and Appointment of Dr. Thierry Abribat as Executive Chairman of the Board

Thryv Therapeutics Announces Positive Phase 1 Results of THRV-1268 in Obese Participants

Specific Biologics Welcomes Accomplished Biotechnology Leader Dr. Richard Glickman to its Board of Directors

Thryv Therapeutics Strengthens Senior Leadership Team with Appointment of Matt Killeen, PhD, as Chief Business Officer

Pathway to Cures Invests in SeraGene Therapeutics

Amy Rudolph, PhD, Joins Thryv Therapeutics’ Board of Directors to Support Portfolio Progression into Heart Failure

Domain Therapeutics Doses First Patients in Phase I/II Trial of DT-7012 Targeting CCR8 in Solid Tumors

Epitopea Strengthens Scientific Advisory Board with Appointment of Four World Renowned Experts in Cancer Immunology and Immunotherapy

Abdera Therapeutics Presents Initial Phase 1 Clinical Data on ABD-147, a Next-generation DLL3-targeting Radiopharmaceutical Therapy, at IASLC 2025 World Conference on Lung Cancer

Thryv Therapeutics Announces FDA IND Clearance of THRV-1268 for Long QT Syndrome

Thryv Therapeutics Receives FDA IND Clearance of THRV-1268 for Heart Failure and Atrial Fibrillation and Presents SGK1 Inhibition Results Combined with Jardiance in Pressure Overload Model at ESC 2025

Epitopea Expands its Clinical Development and Research Capabilities as it Accelerates to the Clinic

9Bio Therapeutics selected by Merck Global Health Innovation Fund and CQDM for strategic investment and acceleration program

Specific Biologics Welcomes Paul J. Hastings as Chair of the Board of Directors

$1.8M Quebec-backed collaboration between 9Bio and Vega advances precision oncology innovation

Zucara Therapeutics Announces Second and Final Closing of US$25 Million Series B Financing

Two key experts joining Find Therapeutics to accelerate the development of FTX-101

9Bio Therapeutics secures strategic funding to advance its oncology pipeline

Epitopea Announces License and Research Collaboration Agreement with MSD to Identify CryptigenTM Tumor-Specific Antigens

Epitopea Announces Nature Cancer Paper on Novel Immunotherapy Targets in Melanoma and NSCLC

KisoJi Biotechnology Raises $41 Million to Advance Lead Program Into the Clinic and Deploy AI Tools Into Key Pipeline Indications

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

Thryv Therapeutics Announces Completion of Phase 1 Dosing of its Second Novel SGK1 Inhibitor THRV-1268 – Future Studies in Heart Failure and Atrial Fibrillation to Commence in 2025

Zucara Therapeutics Announces Strategic Investment from Sanofi as Part of US$20 Million Series B Financing

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers

Epitopea Closes USD $31 million Pre-Series A Financing

Cancer Research UK and KisoJi Biotechnology Collaborate to Advance the First Naked Antibody Against TROP2 Into the Clinic

Find Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of FTX-101

Thryv Therapeutics Receives Positive Top-Line Results from Wave I Part 2 Clinical Study in Long QT Syndrome Type 2 and Type 3 Patients

Thryv Therapeutics Granted FDA Orphan Drug Designation for LQT-1213 in Long QT Syndrome Treatment

NanoVation Therapeutics Announces Multi-Target Partnership with Novo Nordisk to Develop Genetic Medicines Targeting Cardiometabolic and Rare Diseases